Emerging Markets Earnings Roundup: Pfizer, Merck, AbbVie (Part 4)
This article was originally published in PharmAsia News
Executive Summary
AbbVie, Merck and Pfizer had contrasting numbers for their third quarter earnings. While AbbVie rode high on Humira, Merck faced tough conditions in China and Mexico. Pfizer outclassed most global companies in China, with a growth of 8%, which could have doubled had it not transferred some products to its Chinese JV with Hisun.